



Fabhalta in Kuwait

The Kuwait MoH named-patient coordination pathway — indicative 2026

HEMATOLOGY / COMPLEMENT · PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

The clinical situation

Fabhalta (iptacopan) is the first oral, twice-daily monotherapy approved for paroxysmal nocturnal hemoglobinuria (PNH) in adults. Manufactured by Novartis, it inhibits Factor B upstream in the alternative complement pathway — a meaningful differentiator from the IV or SC regimens of Soliris, Ultomiris, and Empaveli. Delivered as 200 mg oral capsules twice daily. It carries a US boxed warning regarding serious infections caused by encapsulated bacteria, which is why pneumococcal, meningococcal (A/C/W/Y and B), and Hib vaccination per current ACIP recommendations is a gating step before therapy begins.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your haematologist confirms PNH diagnosis (flow cytometry) and documents any prior C5-inhibitor exposure.
- 2 Vaccination program.** Pneumococcal, meningococcal (A/C/W/Y and B), and Hib vaccinations per ACIP, ideally completed at least 2 weeks before first dose.
- 3 Kuwait MoH named-patient application.** Physician files dossier: rationale, patient reference, vaccination documentation, twice-daily oral dosing plan.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed specialty wholesale partner, aligned with the manufacturer's controlled-distribution model.
- 5 Arrival & oral dosing start.** Controlled-room-temperature shipment; treating haematologist initiates oral dosing.

Indicative economics

Reference US cash-pay range: USD 500,000–650,000 annualised at US list for PNH (Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

7–14 days from a complete Kuwait MoH application to first dispensed supply; vaccination lead time may extend this. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your haematologist and Kuwait MoH review, including the encapsulated-organism vaccination block. **Logistics.** Controlled-room-temperature shipment with importer-of-record handling. **Concierge case lead.** Named point of contact for family and care team. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating haematologist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Fabhalta × Kuwait first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/fabhalta-kuwait.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team